Affimed NV and Artiva Biotherapeutics Inc. have entered into a new strategic partnership to jointly develop, manufacture and commercialize a combination therapy comprised of Affimed's Innate Cell Engager (ICE) AFM-13 and Artiva's cord blood-derived, cryopreserved off-the-shelf allogeneic natural killer (NK) cell product candidate, AB-101.
Synthetic cells (SCs) armed with recombinant growth factors could contribute to tissue regeneration and healing by promoting angiogenesis. This technology opens the door to its application in other therapies such as transplants that require the remodeling or formation of new blood vessels. In addition, they mark the way to produce intracorporeal biological drugs or the inhibition of the angiogenesis process itself when it comes to blocking the irrigation of a tumor.
Immune checkpoint inhibitors are useful for the treatment of solid tumors, but in many tumors, only partial response is achieved. The antitumoral efficacy of Enlivex Therapeutics Ltd.'s Allocetra-OTS, a cellular therapy, was investigated in animal models of solid tumors.
RSS
